Harrow Health is a drug manufacturers - specialty & generic business based in the US. Harrow Health shares (HROW) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $42.90 – an increase of 9.97% over the previous week. Harrow Health employs 315 staff and has a trailing 12-month revenue of around $169.1 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $42.90 |
|---|---|
| 52-week range | $8.72 - $59.23 |
| 50-day moving average | $47.88 |
| 200-day moving average | $26.94 |
| Wall St. target price | $60.85 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-0.95 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $42.9 from 2024-11-22
| 1 week (2024-11-18) | 12.98% |
|---|---|
| 1 month (2024-10-25) | -15.22% |
| 3 months (2024-08-23) | 0.47% |
| 6 months (2024-05-24) | 139.80% |
| 1 year (2023-11-24) | 357.36% |
|---|---|
| 2 years (2022-11-25) | 294.66% |
| 3 years (2021-11-24) | 320.18% |
| 5 years (2019-11-25) | 619.80% |
Valuing Harrow Health stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Harrow Health's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Harrow Health's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $2.7 million.
The EBITDA is a measure of a Harrow Health's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $169.1 million |
|---|---|
| Operating margin TTM | 2.68% |
| Gross profit TTM | $63.2 million |
| Return on assets TTM | -1.68% |
| Return on equity TTM | -50.23% |
| Profit margin | -19.75% |
| Book value | $1.64 |
| Market Capitalization | $1.5 billion |
TTM: trailing 12 months
We're not expecting Harrow Health to pay a dividend over the next 12 months.
Harrow Health's shares were split on a 1:5 basis on 7 February 2013 . So if you had owned 5 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Harrow Health shares – just the quantity. However, indirectly, the new 400% higher share price could have impacted the market appetite for Harrow Health shares which in turn could have impacted Harrow Health's share price.
Over the last 12 months, Harrow Health's shares have ranged in value from as little as $8.72 up to $59.23. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Harrow Health's is 0.763. This would suggest that Harrow Health's shares are less volatile than average (for this exchange).
Harrow, Inc. , an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract surgery; VIGAMOX, a fluoroquinolone antibiotic eye drop for the treatment of bacterial conjunctivitis; MAXIDEX and FLAREX, a steroid eye drop for steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe and the eye; TRIESENCE, a steroid injection for the treatment of ophthalmic diseases and for visualization during vitrectomy; and NATACYN, a sterile, antifungal drug for the treatment of fungal blepharitis, conjunctivitis, and keratitis. In addition, it offers TOBRADEX ST, a tobramycin and dexamethasone ophthalmic suspension; VERKAZIA cyclosporine ophthalmic emulsion; NEVANAC, a non-steroidal, anti-inflammatory eye drop; and FRESHKOTE preservative free (PF) is a lubricant eye drop. Further, the company has collaboration with Asembia to enhance provider and patient experience through nationwide digital services and hub support for harrow's branded eyecare products. The company was formerly known as Harrow Health, Inc.
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2024 according to Finder’s comprehensive review.
The best platforms to use for automatic investing include Wealthfront, SoFi, Schwab, Vanguard, Titan, Acorns and more. See our full list here.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
5 Betterment robo-advisor alternatives to consider when building your portfolio.
What you need to know about investing in the leading indicator for the overall US stock market.
How do you gift stocks to loved ones? Learn the ins and outs of finding the right investments for them.
Check out the best-performing ETFs so far in 2024.
Acorns is a financial service that rounds up your purchases and turns the extra change into investments.